The insulin receptor is an integral membrane protein comprised of two extracellular a-subunits that bind insulin and two transmembrane b-subunits. The metabolic and growth-promoting effects of insulin are initiated by its binding to the a-subunit of the insulin receptor. Upon binding to insulin, the insulin receptor undergoes autophosphorylation on tyrosine residues, which activates the intracellular tyrosine kinase of the b-subunit. This, in turn, stimulates the phosphorylation of cytoplasmic proteins, including insulin receptor substrate-1 (IRS-1) [1±5].
associated with increased cellular proliferation through the activation of growth factor mitogenic pathways. High glucose concentrations have been shown to enhance cellular proliferation through various mechanisms, including protein kinase C (PKC) activation, platelet-derived growth factor-b (PDGFb) receptor upregulation and increased proteoglycan synthesis [6±9] . The correlation between impaired insulin signalling, another characteristic of diabetes, and increased growth factor pathways or cellular proliferation is not yet known.
Insulin-like growth factor-1, which has many of the structural and functional properties of insulin, is a mediator of cell growth and differentiation. This growth factor and insulin have been shown to possess structurally similar tyrosine kinase receptors and qualitatively similar metabolic and anabolic effects in vivo. Since the effects of both are mediated through phosphorylation of IRS-1 [10] , IGF-1 may also contribute to diabetic complications. For example, in experimental diabetes, increases in renal IGF-1 and IGF-1 receptor mRNA, and enhanced concentrations of IGF-1 receptor protein have been observed [11] . In addition, glomerular mesangial cells from diabetic mice have been found to express higher numbers of IGF-1 and IGF-1 receptors than cells from control mice [12, 13] . In patients with proliferative diabetic retinopathy, enhanced concentrations of IGF-1 have been observed, suggesting that IGF-1 signalling may play a part in the pathogenesis of proliferative diabetic retinopathy [14±16] . There is also ample evidence that IGF-1 stimulates smooth muscle cell growth [17, 18] . Insulin resistance and the aberrant effects of insulin and IGF-1 in vascular tissues are important risk factors for atherosclerosis and are thought to contribute to its development and the development of cardiovascular disease associated with Type II (non-insulin-dependent) diabetes mellitus [19±21] .
To investigate the consequences of impaired insulin signalling on cell growth and transformation, we have established a Chinese hamster ovary (CHO) cell line that stably expresses kinase-negative Thr 1134 mutant insulin receptors, and we have examined the growth and response to growth factors, especially IGF-1, in these insulin-resistant cells.
Materials and methods
Materials. Recombinant human insulin and IGF-1 were obtained from Gibco BRL (Rockville, Md., USA). We obtained [ P]dCTP (37 MBq/mmol) from Amersham Life Science (Tokyo, Japan). Rabbit polyclonal antibodies to insulin receptor b-subunit and carboxy-terminal IRS-1 and mouse monoclonal antibody to phosphotyrosine (4G10) were purchased from Upstate Biotechnology Incorporated (Lake Placid, N. Y., USA). Rabbit polyclonal antibodies to IGF-1 receptor a-subunit, IGF-1 receptor b-subunit, phosphatidyl inositol 3-kinase (PI3K) p85-a (Z-8) and extracellular signal-regulated kinase 2 (ERK2) (C-14), goat polyclonal antibodies to IRS-2, mouse nomoclonal antibody to Shc were purchased from Santa Cruz Biotechnology (Santa Cruz, Calif., USA). Peroxidase-conjugated rabbit antimouse and swine anti-rabbit immunoglobulin were purchased from Dako Japan (Tokyo, Japan). Protein A-agarose, protease inhibitors and phosphatase inhibitors were purchased from Sigma (St. Louis, Mo., USA) and fetal calf serum (FCS) was purchased from Irvine Scientific (Santa Ana, Calif., USA).
Expression plasmids. A cDNA fragment constituting the entire open reading frame of the human insulin receptor was subcloned in the sense orientation into the XbaI site of the mammalian expression vector, pEF Bos (Osaka Bioscience Institute, Osaka, Japan) (pEF Bos HIRC). Site directed mutants of insulin receptor cDNA were constructed from pEF Bos HIRC by the polymerase chain reaction (PCR), using the primers, 5 ¢-ATCGGGACCTGACAGCGAGAAAC-3 ¢, 5 ¢-CTGTGGAAGAACGACACCTCTG-3 ¢, and 5 ¢-GAG-GGCAATGCCAGGGACATCA-3 ¢, to amplify an 803-bp cDNA fragment containing the mutation. This fragment was digested with HincII, and the resulting 684-bp fragment was substituted for the corresponding region of pEF Bos HIRC. The PCR-derived region of the mutant plasmid was sequenced to confirm that only the desired mutation was present (pEF Bos HIR/Thr 1134 ).
Transfection of CHO cells. Subconfluent CHO cells, grown in 6 cm dishes in Ham's F-12 medium containing FCS, were transfected with lipofectoamine (Gibco BRL) containing 1 mg pSVE-neo, alone or together with pEF Bos HIR/Thr 1134 , at a molar ratio of 1:10. After 48-h exposure to DNA, the cells were trypsinized and replated at a 1:10 dilution. After 72 h, 800 mg/ml geneticin (Gibco BRL) was added to the medium to select for neomycin-resistant cells, and this medium was changed every 4 to 5 days. Independent colonies were picked and maintained in Ham's F-12 medium, supplemented with 10 % FCS, 100 units/ml penicillin, 100 mg/ml streptomycin and 800 mg/ml geneticin at 37°C in 5% CO 2 . Two independent clonal cell lines expressing a large number of Thr 1134 insulin receptors were chosen for further studies (CHO-mut1 and CHOmut2). [22] . The cells were washed with binding buffer and solubilized in 0.5 ml lysing buffer (0.1 % SDS, 100 mmol/l NaOH). Cell bound and free radioactivity were measured with a gamma counter. Nonspecific binding to cells was usually less than 10 % of total binding. Least-squares analysis was used to assess Scatchard plots.
Effects of growth factors on DNA synthesis. We assayed DNA synthesis by [ 3 H]thymidine incorporation [23] . Subconfluent CHO cells seeded in 96-well plates were incubated for 24 h in Ham's F-12 medium supplemented with 0.1 % BSA to induce quiescence. The medium was replaced with various concentrations of growth factors and, after 20 h, cells were pulse-labelled with [ 3 H]thymidine (37 KBq/well) for 4 h. Incorporated radioactivity was quantified with a b-plate system (Pharmasia LKB, Turku, Finland).
2-Deoxyglucose uptake. Chinese hamster ovary cells that were plated in six-well plates, were incubated with insulin at various concentrations for 1 h at 37°C. Then 2-deoxy-d-[U-
14 C] glucose (2DOG) (14.8 KBq) and 0.1 mmol/l unlabelled 2 DOG were added to each well and incubation was continued for a further 20 min.
The cells were solubilized in 0.5 % SDS and aliquots were assessed for protein content and radioactivity [24] .
Glucose incorporation into glycogen. Chinese hamster ovary cells, plated in six-well plates, were incubated with insulin at various concentrations for 1 h at 37°C. Then 74 KBq of [U- 14 C]glucose was added to each well and incubation was continued for 2 h. The cells were solubilized in 0.5 ml KOH and boiled for 30 min. To each sample 2 mg glycogen and ethanol was added and the samples were incubated at 4°C. The precipitates were pelleted by centrifugation and solubilized in water, and radioactivity was determined by liquid scintillation counting [24] .
Immunoprecipitation and western blotting. Subconfluent cells, treated with insulin or IGF-1, were washed twice with icecold phosphate-buffered saline (PBS) and lysed with TNE buffer containing 150 mmol/l NaCl, 10 mmol/l TRIS-HCl pH 7.8, 1 % NP-40, 1 mmol/l EDTA, 100 mmol/l Na 3 VO 4 , 1 mmol/l phenylmethanesulphonyl fluoride (PMSF), 100 units/ml aprotinine and 10 mg/ml a 2 -macroglobulin. The samples were centrifuged, and the protein contents of the supernatants were measured with a Bio-Rad protein assay kit (Hercules, Calif., USA). The supernatants were incubated with the appropriate antibody and protein A-agarose for 2 h at 4 C and the precipitates were washed four times with lysis buffer, resuspended in SDS sample buffer (25 mmol/l TRIS-HCl pH 6.8, 2% SDS, 10 % glycerol, 0.05 % bromophenolblue) and heated to 90 C for 3 min. Proteins were separated on an SDS-gel gradient and transferred to polyvinylidine difluoride membranes (Immovirone PVDF, Millipore, Bedford, Mass., USA) which were incubated with the appropriate primary antibody and then with the appropriate peroxidase-conjugated secondary antibody. Proteins were made visible by fluorography using an enhanced chemiluminescence system (Amersham).
Phosphatidyl inositol 3-kinase activity. Cell lysates (500 mg) were incubated with a polyclonal antibody against the p85 subunit of PI3K and protein A-agarose, and the precipitates were washed twice with 20 mmol/l TRIS-HCl (pH 7.8), 140 mmol/l NaCl, 1 mmol/l dithiothreitol, 1 % NP-40, twice with 100 mmol/l TRIS-HCl (pH 7.4), 500 mmol/l LiCl, 1 mmol/l dithiothreitol and twice with 10 mmol/l TRIS-HCl (pH 7.4), ]ATP. After 10 min at 30°C, the reaction was stopped by adding 250 ml 1 N HCl and 80 ml CHCl 3 :methanol (2:1). Lipid phosphorylation was analysed by thin-layer chromatography on silica gel plates coated with 1 % potassium oxalate, followed by autoradiography.
Northern blot analysis of IRS-1 mRNA. Aliquots of total RNA (20 mg), extracted from quiescent CHO cells [25] , were electrophoresed through 1 % agarose gels and transferred to nylon membranes (Hybond N; Amersham), which were incubated with a random primed [ 32 P]-labelled mouse IRS-1 gene. The membranes were washed and subjected to autoradiography, and mRNA abundance was measured by scanning laser densitometry and brought to normal against 18S rRNA.
Measurement of cell growth in low serum concentration. Chinese hamster ovary cell proliferation in low serum concentration was assessed as described previously [26] . These cells were seeded at a density of 10 000 cells in six-well plates containing Ham's F-12 plus 0.1 % FCS. Replicate plates were counted 24 h later (day 0) to confirm that all of the plates contained approximately the same initial cell number. The culture medium was changed every 2 days and cell counts were carried out each time. For each condition, experiments were carried out in triplicate.
Statistical analysis. All data is reported as means ± SD and analysed by the non-paired Student's t-test. A p value of less than 0.05 was considered statistically significant.
Results

Insulin receptor analysis. Binding experiments with [
125 I]insulin showed that the number of receptors on the surface of CHO-mut1 and CHO-mut2 cells was 84 and 97 times that on CHO-neo cells (58700/cell and 67200/cell vs 696/cell), whereas the affinity of insulin for its receptor was similar on both cell lines (K d : 0.89 nmol/l and 0.78 nmol/l vs 0.72 nmol/l).
When we assayed cellular insulin receptor concentrations by immunoblotting, we found that the result was similar to that of the Scatchard analysis (data not shown).
Dominant negative effect of insulin receptor. To show that insulin-mediated signal transduction is reduced in CHO-mut cells and that this is due to a dominantnegative effect, we assayed insulin-induced [ Basal levels of all three variables were similar in CHO-mut and CHO-neo cells (Fig. 1) . Treatment of CHO-mut1 and 2 cells with 10 ±9 mol/l insulin reduced [ 3 H]thymidine incorporation 10 % and 11 %, and treatment with 10 ±8 mol/l insulin reduced incorporation 30 % and 26 % compared with control cells (Fig. 1A) . Similarly, in CHO-mut cells, 2DOG uptake was decreased 27 % and 20 % at 10 ±9 mol/l insulin and 31 % and 30 % at 10 ±8 mol/l insulin (Fig. 1B) , and glucose incorporation into glycogen was decreased 21 % and 23 % at 10 ±9 mol/l insulin and 33 % and 28 % at 10 ±8 mol/l insulin compared with control cells (Fig. 1C) .
These results suggest that the kinase-deficient receptor exerts a trans-dominant-negative effect by forming heterodimers with endogenous murine receptors [1, 27, 28] . ±8 mol/l IGF-1 ( Fig. 2A) . We observed no differences between these cell lines, however, in response to PDGF (Fig. 2B) , b-FGF (Fig. 2C) or HB-EGF (Fig. 2D) .
Insulin-like growth factor-1-stimulated MAPK phosphorylation. Mitogen-activated protein kinase (MAPK) is a serine/threonine kinase that is rapidly activated in response to insulin and IGF-1; it has been implicated in cellular proliferation. We assayed the phosphorylation state of p42 (ERK2) MAPK in CHO-mut and CHO-neo cells by an electrophoretic mobility shift assay where the activated, phosphorylated form of ERK2 displays a slower electrophoretic mobility. When stimulated with 10 ±9 mol/l IGF-1, the amount of phosphorylated p42 MAPK in CHO-mut cells was higher than that in CHO-neo cells (Fig. 3A) . We also assayed total levels of MAPK in CHO-mut and CHO-neo cells by western blotting and found no difference between these cell lines (Fig. 3B) . The enzymatic activity of MAPK, assessed by in-gel phosphorylation [29] was parallel to the results of the gel-shift assay (data not shown).
Insulin-like growth factor-1-stimulated PI3K activation. Phosphatidyl inositol 3-kinase is another major component of the IRS-1 mediated insulin and IGF-1 signalling pathways; it contains two Src homology-2 (SH2) domains in its 85-kDa subunit that bind to tyrosine-phosphorylated IRS-1.
We assayed activated PI3K in CHO-mut and CHO-neo cells by immunoprecipitating solubilized cell proteins with anti-IRS-1 antibody and immunoblotting with anti-PI3K antibody. After stimulation with 10 ±9 mol/l IGF-1, the amount of activated PI3K in CHO-mut cells was higher than that in CHO-neo cells (Fig. 4A) .
We also assayed PI3K activity in these cells by measuring [g- 32 P]ATP incorporation into phosphatidyl inositol; PI3K enzyme activity was greater in stimulated CHO-mut cells than in CHO-neo cells (Fig. 4B) .
IGF-1 receptor analysis. When we assayed IGF-1 receptors by binding studies with [
125 I]IGF-1, we found that both the affinity and the number of IGF-1 receptors on CHO-mut1 and 2 cells and CHO-neo cells were similar, with a K d 1.52 and 1.48 nmol/l compared with 1.51 nmol/l, respectively, and a receptor number of 9018 and 9978/cell compared with 9752/cell, respectively.
Stimulation of IGF-1 receptor tyrosine phosphorylation by IGF-1. We assayed tyrosine phosphorylation of IGF-1 receptor in CHO-mut and CHO-neo cells by immunoprecipitation of solubilized cell proteins with anti-IGF-1 receptor b-subunit antibody and immunoblotting with anti-phosphotyrosine antibody. Insulin-like growth factor-1 receptor phosphorylation by IGF-1 was similar in both cell lines (Fig. 5) . Western blotting with an anti-IGF-1 receptor a-subunit antibody showed a similar concentration of IGF-1 receptor on CHO-mut and CHO-neo cells (Fig. 5) , suggesting that augmented IGF-1 signalling in CHO-mut cells was not due to changed IGF-1 receptor expression or affinity. Stimulation of IRS-1 tyrosine phosphorylation by IGF-1. Insulin receptor substrate-1 is a major intracellular substrate for the tyrosine phosphorylases of insulin receptor and IGF-1 receptor; it is phosphorylated immediately following insulin or IGF-1 stimulation, and it has a key role in the intracellular signalling cascade that includes MAPK and PI3K [1±3, 30, 31] .
We assayed tyrosine phosphorylation of IRS-1 in CHO-mut and CHO-neo cells by immunoprecipitation of solubilized cell proteins with anti-IRS-1 antibody and immunoblotting with anti-phosphotyrosine antibody. Although IRS-1 phosphorylation was nearly undetectable in the absence of IGF-1, it was higher in CHO-mut cells than in CHO-neo cells after stimulation with 10 ±9 mol/l and 10 ±7 mol/l IGF-1 (Fig. 6 ). When we assayed IRS-1 expression by western blotting with anti-IRS-1 antibody, we found it was higher in CHO-mut cells than in CHO-neo cells (Fig. 6) .
Stimulation of IRS-2 and Shc tyrosine phosphorylation by IGF-1. Insulin receptor substrate-2 and Shc are also important substrates of insulin and IGF-1 receptors. So, we measured the tyrosine phosphorylation and protein of IRS-2 and Shc and found no statistically significant differences in the phosphorylation after stimulation with IGF-1 or in the expression of IRS-2 and Shc by western blotting (Fig. 7) .
Insulin receptor substrate-1 mRNA expression. To study whether the increased IRS-1 protein expression is due to an increase in gene transcription, we assayed IRS-1 mRNA expression by northern blotting. We observed a twofold increase in message abundance in CHO-mut cells compared with CHO-neo cells (Fig. 8) .
Cell growth in low serum concentration. Cells overexpressing IRS-1 have been reported to display transformed phenotypes [26, 32, 33] .
To determine whether the increased IRS-1 expression observed in CHO-mut cells has any effect on cell growth, we investigated cell proliferation in medium containing 0.1 % FCS. We observed increased growth of CHO-mut compared with CHO-neo cells, resulting in about double the cell number in 8 days (Fig. 9 ).
Discussion
Although hyperglycaemia as well as diabetic complications, including retinopathy, nephropathy and atherosclerosis, have been shown to be closely associated with increased cellular proliferation, the effect of impaired insulin signalling, another characteristic of diabetes, on cell growth regulation had not been clar- The authors who reported the A/T 1134 mutant investigated the insulin response in CHO cells overexpressing this mutant. They found an inhibition of glycogen synthesis in response to insulin in mutant cell lines, however, insulin-stimulated thymidine incorporation and glucose uptake in two mutant cell lines were not different from those in control cells [24] . This could have resulted from differences in insulin concentration and time of stimulation. In a similar study using another kinase-deficient mutant of the insulin receptor (A/K1018), it was reported that both insulin and IGF-1 responses were decreased in the mutant cell lines [34] . It has been proposed that mutant insulin receptors form hybrid oligomers with wild-type IGF-1 receptors and that such oligomers are defective in kinase activity. In this respect, the variability of the IGF-1 response could be attributed to the different phenotypic expression of heterozygous mutations in the insulin receptor kinase domain. Compared with the A/K1018 mutant insulin receptor, the A/T1134 mutant insulin receptor could have a different phosphorylation site for the receptor and IRS-1, a different binding site and affinity with IRS-1 and cause different IRS-1 metabolism, resulting in augumented IGF-1 signalling. It might be interesting to include both insulin receptor mutations for comparison to establish whether the enhanced IGF-1 signalling is a phenomenon linked to insulin resistance, or whether this is unique to the Thr 1134 insulin receptor mutation. It is also reported that the Ile 1153 mutant receptor retains the ability to bind IRS-1 and that sequestration or serine/threonine phosphorylation of the substrate or both may provide an alternative molecular explanation for the dominant negative effect of the mutant receptor to inhibit phosphorylation of IRS-1 and inhibition of IRS-1 tyrosine phosphorylation by kinase competent IGF-1 receptors [35, 36] . Because this explanation is applicable in the presence of insulin stimulation, it can be speculated that in the quiescent condition, mutant insulin receptors have no effect on IRS-1 phosphorylation by the IGF-1 receptor and that sequestration and serine/threonine phosphorylation of IRS-1 by mutant insulin receptors influence IRS-1 metabolism, resulting in increased IRS-1 expression and augumented IRS-1 phosphorylation by IGF-1 stimulation.
In patients with naturally occuring insulin receptor mutations, IGF-1 signalling has been shown to be impaired in vivo but it was reported that this could be due to the impaired production of IGF-1 and accerelated excretion by impaired IGF binding protein-3 production [37] . Moreover, it has been reported that treatment with recombinant human IGF-1 improved glucose metabolism in patients with insulin receptor mutations and severe insulin resistance [38±40] therefore responsiveness to IGF-1 is possibly not so impaired and could even be increased in some conditions in vivo. Our observations of augumented IGF-1 signalling suggest new therapeutic roles and potential for recombinant human IGF-1 in subjects with insulin receptor mutations. At the same time, however, IGF-1 treatment for a prolonged period may accerelate progression of diabetic complications by cell growth promotion.
Insulin receptor substrate-1 acts as a multiple docking protein by binding to downstream signaltransduction molecules in response to activation by insulin or IGF-1. Phosphorylation of multiple tyrosine residues of IRS-1 by insulin or IGF-1 receptors has been shown to result in the association of IRS-1 with the SH2 domains of other cytoplasmic signalling proteins, including PI3K, Syp, GRB2 and Nyc [41] . Consequently, IRS-1 mediates the activation of PI3K, p70S6-kinase, p21Ras and MAPK, resulting in the promotion of glucose uptake, glycogen synthesis, mitogenesis and gene expression, thus serving as an important point in the insulin or IGF-1 action pathway at which the signal diverges to produce the multiple biological effects of the hormone. When we assayed the effects of IGF-1 on IRS-1 in CHO-mut cells, we found that tyrosine phosphorylation of this protein, as well as the protein expression, were higher in CHO-mut than in CHO-neo cells. This indicates that the increased IRS-1 phosphorylation, MAPK activity and PI3K activity observed in the former could be due to, and parallel, increased IRS-1 protein expression.
Insulin receptor substrate-1 has been found to be overexpressed in human hepatocellular carcinomas, suggesting that this protein may be important in hepatocyte transformation, as well as in the physiological proliferation of these cells [26, 32, 33] . In human cancer cells, which are responsive to IGF-1, increased expression and tyrosine phosphorylation of IRS-1 have been detected, suggesting that the association of IRS-1 with cellular transformation could be due to its activity as a substrate for the IGF-1 receptor [42, 43] . Thus, the upregulation of IRS-1 in insulin-resistant CHO-mut cells could induce some phenotypic change, and increased IRS-1 expression in these cells is possibly associated with the increased cellular proliferation observed in diabetic complications.
Long-term insulin treatment has been reported to induce decreased levels of IRS-1 protein. In CHO cells, insulin has been found to decrease IRS-1 content [44] . Treating Fao cells and also 3T3-F442A adipocytes with insulin for a long term has also been shown to decrease IRS-1 protein and phosphorylation levels [45±50] . Since the concentration of insulin that produces a 50 % reduction of IRS-1 is between 0.01 and 1 nmol/l, well within the physiological range, our results suggest that impaired insulin signalling in CHO-mut cells may induce a relative increase in IRS-1 protein levels. Although insulin-induced downregulation of IRS-1 in other cells has been shown to be due to an increased rate of degradation of IRS-1 protein, we have shown in CHO-mut cells that increased IRS-1 expression is not due to a change in protein turnover but to an increase in IRS-1 mRNA expression. Thus, in various diabetic conditions, impaired insulin signalling may upregulate IRS-1, leading to increased IGF-1 signalling and a change in cell growth.
